Core Viewpoint - Huapu Science and Technology has completed over 100 million yuan in Pre-B round financing, aiming to advance domestic liquid chromatography technology innovation and application, breaking the import monopoly [1][2]. Company Overview - Huapu Science and Technology, established in 2015, has developed a comprehensive product matrix including HPLC (High-Performance Liquid Chromatography), UHPLC (Ultra-High-Performance Liquid Chromatography), and corresponding software and consumables. The company has thousands of its own brand instruments in the mainstream chromatography application market [2][3]. - The company has built a significant competitive advantage in the domestic liquid chromatography field, being one of the few manufacturers capable of entering customs, quality inspection, and drug supervision units, as well as key commercial clients such as pharmaceutical companies and CROs [2]. Market Context - The liquid chromatography market in China is valued at over 10 billion yuan annually, with more than 90% of the market currently dominated by imported brands. The industry is characterized by a high trade deficit, with imports of precision instruments reaching 90.98 billion yuan in 2024, surpassing imports of soybeans and integrated circuits [6][8][9]. - The domestic production of liquid chromatography instruments is not only about the autonomy of life science tools but also about ensuring supply chain security for industrial enterprises, research institutions, and government testing units [9]. Product Development and Innovation - Huapu Science and Technology is continuously expanding its product matrix to achieve platform-scale effects. The company has formed strategic partnerships to promote the domestic production of clinical liquid chromatography and mass spectrometry technology [3][5]. - The company has achieved over 95% localization of core components in its chromatography instruments, ensuring a fully controllable upstream supply chain, which mitigates potential risks from trade disputes [10]. Regulatory Compliance and Software Development - The development of compliant chromatography software is a major bottleneck for domestic liquid chromatography products entering the mainstream market. Huapu has spent eight years developing a fully independent, compliant chromatography control software that meets international regulatory standards [11][12]. - The software is crucial for process control and data storage in drug development and production, serving as an important quality defense for regulatory agencies and large pharmaceutical companies [10]. Customer Engagement and Market Strategy - Huapu Science and Technology has established a comprehensive marketing system that covers market dominance, sales operations, industry solutions, and technical support, enabling rapid response to customer needs [14]. - The company focuses on key growth engines by targeting policy benchmark clients such as customs and drug supervision, as well as commercial benchmark clients like large pharmaceutical companies and CROs, maintaining high business growth over the past three years [14]. Investment and Future Outlook - The recent financing will accelerate the expansion of domestic and international sales channels and enhance the development of next-generation core products. The company aims to integrate cutting-edge technology and innovative concepts to drive industry innovation [15]. - Investors view Huapu as a key player in the domestic liquid chromatography market, emphasizing the importance of its technology and market expansion capabilities in contributing to the development of China's high-end instrument industry [16][17].